@article{JTD16989,
author = {Pietro Bertoglio and Vittorio Aprile and Marcello Carlo Ambrogi and Alfredo Mussi and Marco Lucchi},
title = {The role of intracavitary therapies in the treatment of malignant pleural mesothelioma},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 2},
year = {2017},
keywords = {},
abstract = {Surgery is one of the steps of multimodality approach for the treatment of MPM. Due to anatomical features, microscopically radical (R0) resection is never possible and a Macroscopic Complete Resection (R1) is considered the target for mesothelioma surgeons. Recently, intracavitary therapies have been described with the aim of extending the loco-regional effect of surgery. Different agents might be administered intrapleurally: chemotherapy drugs are the most widely used, but also photodynamic therapy (PDT) showed to lead to satisfactory long-term outcomes; furthermore, immunotherapies and gene therapies have been also reported. Despite promising results, no high-quality evidences are currently available and controlled randomized trials are required to establish the exact role of intracavitary therapies and to standardize the technique.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/16989}
}